NTRK Fusion Gene Positive Advanced Solid Tumor Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| CAGR | 5.40 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
NTRK Fusion Gene Positive Advanced Solid Tumor Market Analysis
The NTRK Fusion Gene Positive Advanced Solid Tumor market is anticipated to grow with a CAGR of nearly 5.4%, during the forecast period.
Certain factors that are driving the market growth include increasing prevalence of cancer and growing research and development activities. Globally, cancer is one of the leading causes of death. The disease witnessed significant growth in the last few decades, and it is expected to grow rapidly over the forecast period.
The World Health Organization (WHO) estimates the rate of cancer number to increase by 70% over the next two decades. Additionally, the increased burden of several lifestyle disorders is also expected to drive the market, as biomarkers play a vital role in risk assessment, early diagnosis, and effective monitoring of treatment.
FDA's approval of entrectinib for neurotrophic tyrosine receptor kinase (NTRK) fusion-positive tumors represents a new paradigm in cancer treatment. It treats a cancer based on a common biomarker seen across different tumors rather than based on the location in the body where the cancer originated.
NTRK Fusion Gene Positive Advanced Solid Tumor Market Trends
This section covers the major market trends shaping the NTRK Fusion Gene Positive Advanced Solid Tumor Market according to our research experts:
Diagnostics Segment Holds Significant Share in the Global NTRK Fusion Gene Positive Advanced Solid Tumor Market
There are multiple methods for identifying NTRK fusions, including pan-TRK immunohistochemistry, fluorescence in situ hybridization and sequencing methods. FISH and RT-PCR have been successfully used in the clinic to detect NTRK fusions and are reasonable alternatives to NGS, especially for tumor histologies with a high prevalence of NTRK fusions involving recurrent partners (MASC, infantile fibrosarcomas, secretory breast carcinoma, and cellular or mixed congenital mesoblastic nephromas). Recent approvals add to the growth of the segment share. In 2018, SeraCare Life Sciences, a manufacturer and leading partner to global in vitro diagnostics manufacturers and clinical laboratories, launched an expanded neurotrophic tropomyosin receptor kinase (NTRK) RNA fusion reference material panel developed in a partnership with Bayer.
North America Dominates the Global NTRK Fusion Gene Positive Advanced Solid Tumor Market
As per the American Cancer Society, in 2018, the United States witnessed around 164,690 new cases of prostate cancer, causing over 26,430 deaths. About 60% of the total prostate cancer cases diagnosed are among men aged 65 years or older. In order to tackle such challenges, extensive research in the field of diagnostics has been undertaken.
The ease in the US government regulations and availability of funds from various organizations, like the National Institute of Health, have provided the potential for researchers to invest more in the use of fusion genes in drug discovery, drug development, detection of specific tumors, monitoring biological response to cancer therapy, and genetic studies for the identification of predisposed candidates of cancer.
NTRK Fusion Gene Positive Advanced Solid Tumor Industry Overview
The global NTRK Fusion Gene Positive Advanced Solid Tumor market is competitive and consists of a few major players. Companies like Bayer AG, Cephalon, Inc., Empire Genomics, LLC., Exelixis, Inc, F. Hoffmann-La Roche Ltd, NeoGenomics Laboratories, Inc., OncoDNA, among others, hold the substantial market share in the market.
NTRK Fusion Gene Positive Advanced Solid Tumor Market Leaders
-
Bayer AG
-
Empire Genomics, LLC
-
F. Hoffmann-La Roche Ltd.
-
NeoGenomics Laboratories, Inc.
-
OncoDNA
*Disclaimer: Major Players sorted in no particular order
NTRK Fusion Gene Positive Advanced Solid Tumor Market Report - Table of Contents
-
1. INTRODUCTION
-
1.1 Study Deliverables
-
1.2 Study Assumptions
-
1.3 Scope of the Study
-
-
2. RESEARCH METHODOLOGY
-
3. EXECUTIVE SUMMARY
-
4. MARKET DYNAMICS
-
4.1 Market Overview
-
4.2 Market Drivers
-
4.2.1 Increasing Prevalence of Cancer
-
4.2.2 Growing Research and Development Activities
-
-
4.3 Market Restraints
-
4.3.1 Poor Healthcare Infrastructure and High Costs associated with Genetic Screening of NTRK Fusion Genes
-
-
4.4 Porter's Five Force Analysis
-
4.4.1 Threat of New Entrants
-
4.4.2 Bargaining Power of Buyers/Consumers
-
4.4.3 Bargaining Power of Suppliers
-
4.4.4 Threat of Substitute Products
-
4.4.5 Intensity of Competitive Rivalry
-
-
-
5. MARKET SEGMENTATION
-
5.1 By Type
-
5.1.1 By Therapeutics
-
5.1.2 By Diagnostics
-
-
5.2 By End-User
-
5.2.1 Hospitals and Clinics
-
5.2.2 Cancer Centers
-
5.2.3 Others
-
-
5.3 Geography
-
5.3.1 North America
-
5.3.1.1 United States
-
5.3.1.2 Canada
-
5.3.1.3 Mexico
-
-
5.3.2 Europe
-
5.3.2.1 Germany
-
5.3.2.2 United Kingdom
-
5.3.2.3 France
-
5.3.2.4 Italy
-
5.3.2.5 Spain
-
5.3.2.6 Rest of Europe
-
-
5.3.3 Asia-Pacific
-
5.3.3.1 China
-
5.3.3.2 Japan
-
5.3.3.3 India
-
5.3.3.4 Australia
-
5.3.3.5 South Korea
-
5.3.3.6 Rest of Asia-Pacific
-
-
5.3.4 Middle-East and Africa
-
5.3.4.1 GCC
-
5.3.4.2 South Africa
-
5.3.4.3 Rest of Middle-East and Africa
-
-
5.3.5 South America
-
5.3.5.1 Brazil
-
5.3.5.2 Argentina
-
5.3.5.3 Rest of South America
-
-
-
-
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
-
6.1.1 Bayer AG
-
6.1.2 Teva Pharmaceuticals
-
6.1.3 Empire Genomics, LLC.
-
6.1.4 SeraCare Life Sciences
-
6.1.5 F. Hoffmann-La Roche Ltd
-
6.1.6 NeoGenomics Laboratories, Inc.
-
6.1.7 OncoDNA
-
- *List Not Exhaustive
-
-
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
NTRK Fusion Gene Positive Advanced Solid Tumor Industry Segmentation
NTRK gene fusions involving either NTRK1, NTRK2, or NTRK3 (encoding the neurotrophin receptors TRKA, TRKB, and TRKC, respectively) are oncogenic drivers of various adult and paediatric tumour types. These fusions can be detected in the clinic using a variety of methods, including tumour DNA and RNA sequencing and plasma cell-free DNA profiling. The treatment of patients with NTRK fusion-positive cancers with a first-generation TRK inhibitor, such as larotrectinib or entrectinib, is associated with high response rates.
| By Type | |
| By Therapeutics | |
| By Diagnostics |
| By End-User | |
| Hospitals and Clinics | |
| Cancer Centers | |
| Others |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
NTRK Fusion Gene Positive Advanced Solid Tumor Market Research FAQs
What is the current NTRK Fusion Gene Positive Advanced Solid Tumor Market size?
The NTRK Fusion Gene Positive Advanced Solid Tumor Market is projected to register a CAGR of 5.40% during the forecast period (2024-2029)
Who are the key players in NTRK Fusion Gene Positive Advanced Solid Tumor Market?
Bayer AG , Empire Genomics, LLC, F. Hoffmann-La Roche Ltd. , NeoGenomics Laboratories, Inc. and OncoDNA are the major companies operating in the NTRK Fusion Gene Positive Advanced Solid Tumor Market.
Which is the fastest growing region in NTRK Fusion Gene Positive Advanced Solid Tumor Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in NTRK Fusion Gene Positive Advanced Solid Tumor Market?
In 2024, the North America accounts for the largest market share in NTRK Fusion Gene Positive Advanced Solid Tumor Market.
What years does this NTRK Fusion Gene Positive Advanced Solid Tumor Market cover?
The report covers the NTRK Fusion Gene Positive Advanced Solid Tumor Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the NTRK Fusion Gene Positive Advanced Solid Tumor Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
NTRK Fusion Gene Positive Advanced Solid Tumor Industry Report
Statistics for the 2024 NTRK Fusion Gene Positive Advanced Solid Tumor market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. NTRK Fusion Gene Positive Advanced Solid Tumor analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
